Security threats in network coding-enabled mobile small cells

The recent explosive growth of mobile data traffic, the continuously growing demand for higher data rates, and the steadily increasing pressure for higher mobility have led to the fifth-generation mobile networks. To this end, network-coding (NC)-enabled mobile small cells are considered as a promising 5G technology to cover the urban landscape by being set up on-demand at any place, and at any time on any device. In particular, this emerging paradigm has the potential to provide significant benefits to mobile networks as it can decrease packet transmission in wireless multicast, provide network capacity improvement, and achieve robustness to packet losses with low energy consumption. However, despite these significant advantages, NC-enabled mobile small cells are vulnerable to various types of attacks due to the inherent vulnerabilities of NC. Therefore, in this paper, we provide a categorization of potential security attacks in NC-enabled mobile small cells. Particularly, our focus is on the identification and categorization of the main potential security attacks on a scenario architecture of the ongoing EU funded H2020-MSCA project “SECRET” being focused on secure network coding-enabled mobile small cells

Dynamics of the intratumoral immune response during progression of high-grade serous ovarian cancer

PURPOSE: Tumor-infiltrating lymphocytes (TILs) have an established impact on the prognosis of high-grade serous ovarian carcinoma (HGSOC), however, their role in recurrent ovarian cancer is largely unknown. We therefore systematically investigated TIL densities and MHC class I and II (MHC1, 2) expression in the progression of HGSOC. EXPERIMENTAL DESIGN: CD3+, CD4+, CD8+ TILs and MHC1, 2 expression were evaluated by immunohistochemistry on tissue microarrays in 113 paired primary and recurrent HGSOC. TILs were quantified by image analysis. All patients had been included to the EU-funded OCTIPS FP7 project. RESULTS: CD3+, CD4+, CD8+ TILs and MHC1 and MHC2 expression showed significant correlations between primary and recurrent tumor levels (Spearman rho 0.427, 0.533, 0.361, 0.456, 0.526 respectively; P<.0001 each). Paired testing revealed higher CD4+ densities and MHC1 expression in recurrent tumors (Wilcoxon P=.034 and P=.018). There was also a shift towards higher CD3+ TILs levels in recurrent carcinomas when analyzing platinum-sensitive tumors only (Wilcoxon P=.026) and in pairs with recurrent tumor tissue from first relapse only (Wilcoxon P=.031). High MHC2 expression was the only parameter to be significantly linked to prolonged progression-free survival after first relapse (PFS2, log-rank P=.012). CONCLUSIONS: This is the first study that analyzed the development of TILs density and MHC expression in paired primary and recurrent HGSOC. The level of the antitumoral immune response in recurrent tumors was clearly dependent on the one in the primary tumor. Our data contribute to the understanding of temporal heterogeneity of HGSOC immune microenvironment and have implications for selection of samples for biomarker testing in the setting of immune-targeting therapeutics

Key management for secure network coding-enabled mobile small cells

The continuous growth in wireless devices connected to the Internet and the increasing demand for higher data rates put ever increasing pressure on the 4G cellular network. The EU funded H2020-MSCA project “SECRET” investigates a scenario architecture to cover the urban landscape for the upcoming 5G cellular network. The studied scenario architecture combines multi-hop device-to-device (D2D) communication with network coding-enabled mobile small cells. In this scenario architecture, mobile nodes benefit from high transmission speeds, low latency and increased energy efficiency, while the cellular network benefits from a reduced workload of its base stations. However, this scenario architecture faces various security and privacy challenges. These challenges can be addressed using cryptographic techniques and protocols, assuming that a key management scheme is able to provide mobile nodes with secret keys in a secure manner. Unfortunately, existing key management schemes are unable to cover all security and privacy challenges of the studied scenario architecture. Certificateless key management schemes seem promising, although many proposed schemes of this category of key management schemes require a secure channel or lack key update and key revocation procedures. We therefore suggest further research in key management schemes which include secret key sharing among mobile nodes, key revocation, key update and mobile node authentication to fit with our scenario architecture

Probabilistic reconstruction of the tumor progression process in gene regulatory networks in the presence of uncertainty

<p>Abstract</p> <p>Background</p> <p>Accumulation of gene mutations in cells is known to be responsible for tumor progression, driving it from benign states to malignant states. However, previous studies have shown that the detailed sequence of gene mutations, or the steps in tumor progression, may vary from tumor to tumor, making it difficult to infer the exact path that a given type of tumor may have taken.</p> <p>Results</p> <p>In this paper, we propose an effective probabilistic algorithm for reconstructing the tumor progression process based on partial knowledge of the underlying gene regulatory network and the steady state distribution of the gene expression values in a given tumor. We take the BNp (Boolean networks with pertubation) framework to model the gene regulatory networks. We assume that the true network is not exactly known but we are given an uncertainty class of networks that contains the true network. This network uncertainty class arises from our partial knowledge of the true network, typically represented as a set of local pathways that are embedded in the global network. Given the SSD of the cancerous network, we aim to simultaneously identify the true normal (healthy) network and the set of gene mutations that drove the network into the cancerous state. This is achieved by analyzing the effect of gene mutation on the SSD of a gene regulatory network. At each step, the proposed algorithm reduces the uncertainty class by keeping only those networks whose SSDs get close enough to the cancerous SSD as a result of additional gene mutation. These steps are repeated until we can find the best candidate for the true network and the most probable path of tumor progression.</p> <p>Conclusions</p> <p>Simulation results based on both synthetic networks and networks constructed from actual pathway knowledge show that the proposed algorithm can identify the normal network and the actual path of tumor progression with high probability. The algorithm is also robust to model mismatch and allows us to control the trade-off between efficiency and accuracy.</p

HER2 and ESR1 mRNA expression levels and response to neoadjuvant trastuzumab plus chemotherapy in patients with primary breast cancer

Introduction: Recent data suggest that benefit from trastuzumab and chemotherapy might be related to expression of HER2 and estrogen receptor (ESR1). Therefore, we investigated HER2 and ESR1 mRNA levels in core biopsies of HER2-positive breast carcinomas from patients treated within the neoadjuvant GeparQuattro trial. Methods: HER2 levels were centrally analyzed by immunohistochemistry (IHC), silver in-situ hybridization (SISH) and qRT-PCR in 217 pretherapeutic formalin-fixed, paraffin-embedded (FFPE) core biopsies. All tumors had been HER2-positive by local pathology and had been treated with neoadjuvant trastuzumab/ chemotherapy in GeparQuattro. Results: Only 73% of the tumors (158 of 217) were centrally HER2-positive (cHER2-positive) by IHC/SISH, with cHER2-positive tumors showing a significantly higher pCR rate (46.8% vs. 20.3%, p<0.0005). HER2 status by qRT-PCR showed a concordance of 88.5% with the central IHC/SISH status, with a low pCR rate in those tumors that were HER2-negative by mRNA analysis (21.1% vs. 49.6%, p<0.0005). The level of HER2 mRNA expression was linked to response rate in ESR1-positive tumors, but not in ESR1-negative tumors. HER2 mRNA expression was significantly associated with pCR in the HER2-positive/ESR1-positive tumors (p=0.004), but not in HER2-positive/ESR1-negative tumors. Conclusions: Only patients with cHER2-positive tumors - irrespective of the method used - have an increased pCR rate with trastuzumab plus chemotherapy. In patients with cHER2-negative tumors the pCR rate is comparable to the pCR rate in the non-trastuzumab treated HER-negative population. Response to trastuzumab is correlated to HER2 mRNA levels only in ESR1-positive tumors. This study adds further evidence to the different biology of both subsets within the HER2-positive group

Structural and morphological analysis of zinc incorporated non-stoichiometric hydroxyapatite nano powders

ABSTRACT In this study, Zn incorporated non-stoichiometric hydroxyapatite (nHAp) was synthesized via precipitation method and effect of the incorporation of Zn (fraction: 2, 4, 6 and 8 mol-%) on the microstructure of nHAp was studied by XRD, FTIR analysis and SEM-EDS techniques. The formation of nHAp was confirmed by XRD and FTIR those showed that no secondary phase was formed through the Zn incorporation. The SEM studies also revealed that particles were formed in nano-metric size (30-60 nm). It was found that crystallite and particle size of Zn incorporated nHAp gradually decreased up to 6 mol-%, and started to increase while the Zn fraction reached up to the 8 mol-% and hence the morphology of the aggregated products was also changed. It can be concluded that the incorporation of Zn cations cause to form nHAp phase. Furthermore, the nHAp microstructure has deviated from stoichiometric condition by incorporation of more Zn cations

Full deflection profile calculation and Young’s modulus optimisation for engineered high performance materials

New engineered materials have critical applications in different fields in medicine, engineering and technology but their enhanced mechanical performances are significantly affected by the microstructural design and the sintering process used in their manufacture. This work introduces (i) a methodology for the calculation of the full deflection profile from video recordings of bending tests, (ii) an optimisation algorithm for the characterisation of Young’s modulus, (iii) a quantification of the effects of optical distortions and (iv) a comparison with other standard tests. The results presented in this paper show the capabilities of this procedure to evaluate the Young’s modulus of highly stiff materials with greater accuracy than previously possible with bending tests, by employing all the available information from the video recording of the tests. This methodology extends to this class of materials the possibility to evaluate both the elastic modulus and the tensile strength with a single mechanical test, without the need for other experimental tools

Nottingham prognostic index plus (NPI+) predicts risk of distant metastases in primary breast cancer

The Nottingham prognostic index plus (NPI+) is based on the assessment of biological class combined with established clinicopathologic prognostic variables providing improved patient outcome stratification for breast cancer superior to the traditional NPI. This study aimed to determine prognostic capability of the NPI+ in predicting risk of development of distant disease. A well-characterised series of 1073 primary early-stage BC cases treated in Nottingham and 251 cases from Budapest were immunohistochemically assessed for cytokeratin (Ck)5/6, Ck18, EGFR, oestrogen receptor (ER), progesterone receptor, HER2, HER3, HER4, Mucin 1 and p53 expression. NPI+ biological class and prognostic scores were assigned using individual algorithms for each biological class incorporating clinicopathologic parameters and investigated in terms of prediction of distant metastases-free survival (MFS). The NPI+ identified distinct prognostic groups (PG) within each molecular class which were predictive of MFS providing improved patient outcome stratification superior to the traditional NPI. NPI+ PGs, between series, were comparable in predicting patient outcome between series in luminal A, basal p53 altered and HER2+/ER+ (p > 0.01) tumours. The low-risk groups were similarly validated in luminal B, luminal N, basal p53 normal tumours (p > 0.01). Due to small patient numbers the remaining PGs could not be validated. NPI+ was additionally able to predict a higher risk of metastases at certain distant sites. This study may indicate the NPI+ as a useful tool in predicting the risk of metastases. The NPI+ provides accurate risk stratification allowing improved individualised clinical decision making for breast cancer